Cardiometabolic index as a new predictor of non-alcoholic fatty liver disease: Potential for use it in diagnosis and evaluation therapy
Abstract. Non-alcoholic fatty liver disease (NAFLD) is an important component of the cardio-renal-hepato-metabolic continuum, requiring timely diagnosis. Available diagnostic tools do not always accurately detect liver steatosis at early stages. A promising solution in this case is the use of the cardiometabolic index (CMI), which can improve the accuracy of screening and risk stratification. The aim: to evaluate the diagnostic utility of CMI as a potential NAFLD predictor and analyze its dynamics during therapy with ursodeoxycholic acid (UDCA – Ursosan Forte). Material and methods. The study included 120 patients (68 female and 52 male individuals, median age 55 [47; 63] years) with confirmed NAFLD based on abdominal ultrasound and magnetic resonance imaging with proton density adipose tissue evaluation (MRI-PDFF). CMI was calculated basing on anthropometric and laboratory parameters. A subgroup of 30 participants who were prescribed UDCA at a dose of 12 mg/kg of body weight were then followed for 6 months. After 6 months, CMI and MRI-PDFF were recalculated. Results. CMI demonstrated diagnostic value for the early detection of hepatic steatosis. In 84.6% of male and 86.8% of female patients with proven hepatic steatosis, the index values were above the cutoff figures, allowing its use for NAFLD screening. A statistically significant correlation between CMI values and the degree of steatosis was revealed (rs = 0.296, p <0.001), gender differences of this correlation were identified. UDCA therapy (12 mg/kg/day for 6 months in combination with non-pharmacological measures for NAFLD correction) significantly reduced liver fatty infiltration according to MRI-PDFF from 10 to 6.5% (p = 0.008), as well as a decrease in CMI as an integral indicator of cardiometabolic disorders. Conclusion. CMI can be used as an auxiliary tool not only for identifying patients with NAFLD but also for assessing the efficacy of therapy. The use of UDCA promotes steatosis regression and reduces cardiovascular risks.Yu.V. Cheremukhina, N.Yu. Borovkova
Keywords
non-alcoholic fatty liver disease
cardiometabolic index
magnetic resonance imaging with proton density lipid measurement
ursodeoxycholic acid (Ursosan Forte)
References
1. Драпкина О.М., Евстифеева С.Е., Шальнова С.А. Распространенность неалкогольной жировой болезни печени и ее ассоциации с сердечно-сосудистыми факторами риска (данные российских эпидемиологических исследований). Кардиоваскулярная терапия и профилактика. 2025;24(2):6–16. (Drapkina OM, Evstifeeva SE, Shalnova SA. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular risk factors (data from Russian epidemiological studies). Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2025;24(2):6–16 (In Russ.)).
EDN: CVQNXA. https://doi.org/10.15829/1728-8800-2025-4316
2. Драпкина О.М., Недогода С.В. Метаболически ассоциированная жировая болезнь печени при метаболическом синдроме. Российский кардиологический журнал. 2025;30(S1):91–98. (Drapkina OM, Nedogoda SV. Metabolic-associated fatty liver disease in metabolic syndrome. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2025;30(S1):91–98 (In Russ.)).
EDN: QDDYDH. https://doi.org/10.15829/1560-4071-2025-6541
3. Шляхто Е.В., Недогода С.В., Бабенко А.Ю., Арутюнов Г.П., Драпкина О.М., Кобалава Ж.Д. с соавт. Новая концепция кардио-рено-гепато-метаболического синдрома: о чем размышляли эксперты. Российский кардиологический журнал. 2025;30(S1):16– 22. (Shlyakhto EV, Nedogoda SV, Babenko AYu, Arutyunov GP, Drapkina OM, Kobalava ZhD et al. A new concept of cardio-Reno-Hepato-metabolic syndrome: What experts thought about. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2025;30(S1):16–22 (In Russ.)).
EDN: SPGOTN. https://doi.org/10.15829/1560-4071-2025-6534
4. Duan S, Yang D, Xia H, Ren Z, Chen J, Yao S. Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults. Front Endocrinol (Lausanne). 2022;13:1004855.
PMID: 36187093. PMCID: PMC9523727. https://doi.org/10.3389/fendo.2022.1004855
5. Xi WF, Yang AM. Association between cardiometabolic index and controlled weakening parameter in US adults with non-alcoholic fatty liver disease: NHANES (2017–2020) results. Lipids Health Dis. 2024;23(1):40.
PMID: 38326824. PMCID: PMC10851511. https://doi.org/10.1186/s12944-024-02027-x
6. Zhu XM, Xu Y. Cardiometabolic Index is associated with heart failure: A cross-sectional study based on NHANES. Front Med (Lausanne). 2024;11:1507100.
PMID: 39717172. PMCID: PMC11663657. https://doi.org/10.3389/fmed.2024.1507100
About the Authors
Yulia V. Cheremukhina, MD, gastroenterologist at the Department of gastroenterology, N.A. Semashko Nizhny Novgorod Regional Clinical Hospital; assistant at the Department of internal medicine and general medical practice, Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.E-mail: doctor.cheremuhina@gmail.com
ORCID: https://orcid.org/0009-0001-4089-7583
Natalia Yu. Borovkova, MD, Dr. Sci. (Medicine), professor, first deputy director of the Institute of therapy, head of the Department of therapy and general medical practice, Privolzhsky Research Medical University, Nizhny Novgorod, Russian Federation.
E-mail: borovkov-nn@mail.ru
ORCID: https://orcid.org/0000-0001-7581-4138
Similar Articles
